• Je něco špatně v tomto záznamu ?

DPP-4-inhibitors - What are the similarities, where are the differences? [Inhibítory DPP-4 - v čom sú si podobné a čom sa líšia?]

Matthias Blüher

. 2012 ; 1 (1) : 8-16.

Jazyk angličtina, slovenština Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc13005451

With the increasing prevalence of type 2 diabetes and its complications throughout the world, there is a need for efficient and safe therapeutic strategies. The dipeptidyl peptidase-4 (DPP-4) inhibitors have become important oral glucose lowering drugs for the management of patients with type 2 diabetes. All DPP-4-inhibitors act on the incre - tin system to lower hyperglycemia, have a similar safety profile, are well tolerated, do not cause significant weight gain and have a relatively low risk of hypoglycemia. However, there are clinical differences among the four agents, sitagliptin, vildagliptin, saxagliptin, and linagliptin which are currently approved by the US Food and Drug Admi - nistration or the European Medicines Agency. This review article discusses similarities and differences in efficacy, safety and tolerability of these four DPP-4-inhibitors.

Inhibítory DPP-4 - v čom sú si podobné a čom sa líšia?

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc13005451
003      
CZ-PrNML
005      
20160601101302.0
007      
ta
008      
130208s2012 xr f f 000 0eng||
009      
AR
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng $a slo
044    __
$a xr
100    1_
$a Blüher, Matthias $u Faculty of Medicine, University of Leipzig; Germany and University Hospital Leipzig, Department of Internal Medicine III - Department of endocirnology and nephrology, Leipzig
245    10
$a DPP-4-inhibitors - What are the similarities, where are the differences? / $c Matthias Blüher
246    31
$a Inhibítory DPP-4 - v čom sú si podobné a čom sa líšia?
504    __
$a Literatura
520    9_
$a With the increasing prevalence of type 2 diabetes and its complications throughout the world, there is a need for efficient and safe therapeutic strategies. The dipeptidyl peptidase-4 (DPP-4) inhibitors have become important oral glucose lowering drugs for the management of patients with type 2 diabetes. All DPP-4-inhibitors act on the incre - tin system to lower hyperglycemia, have a similar safety profile, are well tolerated, do not cause significant weight gain and have a relatively low risk of hypoglycemia. However, there are clinical differences among the four agents, sitagliptin, vildagliptin, saxagliptin, and linagliptin which are currently approved by the US Food and Drug Admi - nistration or the European Medicines Agency. This review article discusses similarities and differences in efficacy, safety and tolerability of these four DPP-4-inhibitors.
650    12
$a diabetes mellitus 2. typu $x farmakoterapie $x metabolismus $7 D003924
650    12
$a inhibitory dipeptidylpeptidasy 4 $x aplikace a dávkování $x farmakologie $x metabolismus $7 D054873
650    12
$a glukagonu podobný peptid 1 $x účinky léků $7 D052216
650    12
$a inkretiny $x metabolismus $x terapeutické užití $7 D054795
650    12
$a hyperglykemie $x farmakoterapie $7 D006943
650    _2
$a hypoglykemie $x chemicky indukované $x prevence a kontrola $7 D007003
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a hodnocení léčiv $7 D004341
650    _2
$a lidé $7 D006801
773    0_
$t Forum diabetologicum $x 1805-3807 $g Roč. 1, č. 1 (2012), s. 8-16 $w MED00178699
856    41
$y plný text volně přístupný $u https://www.prolekare.cz/casopisy/forum-diabetologicum/2012-1-11/inhibitory-dpp-4-v-com-su-si-podobne-a-v-com-sa-lisia-40663?hl=en
910    __
$a ABA008 $c 140 $y 3 $z 0
990    __
$a 20130208133651 $b ABA008
991    __
$a 20160601101424 $b ABA008
999    __
$a ok $b bmc $g 968348 $s 803676
BAS    __
$a 3
BMC    __
$a 2012 $b 1 $c 1 $i 1805-3807 $m Forum diabetologicum $n Forum Diab $x MED00178699 $d 8-16
LZP    __
$b přidání abstraktu $c NLK125 $d 20130227 $a NLK 2013-09/dk

Najít záznam

Citační ukazatele

Možnosti archivace